Composition of Total Revenue

12 Months Ended

Dec. 31, 2017

Segment Reporting [Abstract]

Composition of Total Revenue

COMPOSITION OF TOTAL REVENUE

The below table presents our net product sales by geography for the years ended December 31, 2017, 2016, and 2015:

	Year Ended December 31,
	2017				2016				2015
United States	$	107,135	92.2	%	$	125,074	97.3	%	$	130,432	95.3	%
International:
Europe	7,727		6.7	%	3,522		2.7	%	2,234		1.6	%
Asia Pacific*	1,316		1.1	%	—		—	%	4,185		3.1	%
Total International	9,043		7.8	%	3,522		2.7	%	6,419		4.7	%
Product sales, net	$	116,178	100.0	%	$	128,596	100.0	%	$	136,851	100.0	%

* See Note 12 for discussion of our November 2015 ZEVALIN out-license for the Asia Pacific territory.

The below table presents our net product sales by drug for the years ended December 31, 2017, 2016, and 2015:

	Year Ended December 31,
	2017				2016				2015
FUSILEV	$	7,300	6.3	%	$	34,839	27.1	%	$	60,710	44.4	%
FOLOTYN	43,015		37.0	%	46,245		36.0	%	40,606		29.7	%
ZEVALIN	11,759		10.1	%	10,730		8.3	%	17,457		12.8	%
MARQIBO	6,573		5.7	%	7,245		5.6	%	8,006		5.9	%
BELEODAQ	12,353		10.6	%	13,368		10.4	%	10,072		7.4	%
EVOMELA	35,178		30.3	%	16,169		12.6	%	—		—	%
Product sales, net	$	116,178	100.0	%	$	128,596	100.0	%	$	136,851	100.0	%

The below table presents our license fees and service revenue by source for the years ended December 31, 2017, 2016, and 2015:

	Year Ended December 31,
	2017				2016				2015
Out-license of FOLOTYN in all countries except the U.S., Canada, Europe, and Turkey: royalties (Note 16)	$	5,848	48.0	%	$	927	5.2	%	$	831	3.2	%
Out-license of ZEVALIN: recognition of upfront cash receipt and subsequent royalties for Asia and certain other territories, excluding China (Note 12)	1,245		10.2	%	1,756		9.8	%	15,144		58.9	%
Out-license of ZEVALIN: amortization of upfront cash receipt related to India territory (Note17(b)(iii)) and other	50		0.4	%	69		0.4	%	48		0.2	%
Out-license of ZEVALIN, FOLOTYN, BELEODAQ, MARQIBO: upfront cash receipt and subsequent royalties for the Canada territory (Note 17(b)(xv))	5		—	%	6,000		33.6	%	—		—	%
Out-license of ZEVALIN, MARQIBO, EVOMELA: upfront receipt for the China territory (Note 11)	—		—	%	—		—	%	9,682		37.7	%
Sales and marketing contracted services (Note 14)	4,747		38.9	%	9,096		51.0	%	—		—	%
Regulatory services provided to licensee	294		2.4	%	—		—	%	—		—	%
License fees and service revenues	$	12,189	100.0	%	$	17,848	100.0	%	$	25,705	100.0	%